PF-06939999

PF-06939999 (PRMT5-IN-3) is a SAM-competitive, orally active PRMT5 inhibitor that inhibits the expression of SDMA protein (IC50 in A427 is 1.1 nM) . PF-06939999 exhibits antitumor effect[1][2].

Product Specifications

CAS Number

[2159123-14-3]

Product Name Alternative

PRMT5-IN-3

UNSPSC

12352005

Target

Apoptosis; Histone Methyltransferase

Type

Reference compound

Related Pathways

Apoptosis; Epigenetics

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/pf-06939999.html

Purity

99.84

Solubility

DMSO : ≥ 100 mg/mL|H2O : 100 mg/mL (ultrasonic)

Smiles

O[C@@H]1[C@H](O)[C@@H](OC2=CC(C(F)F)=C(F)C3=C2CNCC3)C[C@H]1N4C=CC5=C(C)N=CN=C54

Molecular Formula

C22H23F3N4O3

Molecular Weight

448.44

References & Citations

[1]Adli M. Combinatorial drug treatment of cancer. WO2020198601A1.|[2]Jensen-Pergakes K, et al., SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance. Mol Cancer Ther. 2022 Jan;21 (1) :3-15.